Prevention of nosocomical transmission of hepatitis B virus (HBV) has been a signal achievement ill the management of chronic kidney disease. The rate of serum hepatitis B surface antigen (HBsAg) seropositivity in patients on maintenance hemodialysis in the developed world is currently low (0-10%) but outbreaks of acute HBV infection continue to occur in this setting. The prevalence of HBV infection within dialysis units in developing countries appears higher (2-20%) based on relatively few reports. Although data are limited, HBV infection in dialysis population diminishes survival: HBV viral load in HBsAg-positive dialysis p patients is reportedly low and stable over time. Updated recommendations for the management of HBsAg chronic carriers on maintenance dialysis have been issued. No rigorously controlled treatment trials for treatment of hepatitis B with either interferon or lamivudine therapy ill dialysis patients are currently available.
Hepatitis B virus infection and the dialysis patient / F. Fabrizi, P. Messa, P. Martin. - In: SEMINARS IN DIALYSIS. - ISSN 0894-0959. - 21:5(2008), pp. 440-446.
Hepatitis B virus infection and the dialysis patient
P. Messa;
2008
Abstract
Prevention of nosocomical transmission of hepatitis B virus (HBV) has been a signal achievement ill the management of chronic kidney disease. The rate of serum hepatitis B surface antigen (HBsAg) seropositivity in patients on maintenance hemodialysis in the developed world is currently low (0-10%) but outbreaks of acute HBV infection continue to occur in this setting. The prevalence of HBV infection within dialysis units in developing countries appears higher (2-20%) based on relatively few reports. Although data are limited, HBV infection in dialysis population diminishes survival: HBV viral load in HBsAg-positive dialysis p patients is reportedly low and stable over time. Updated recommendations for the management of HBsAg chronic carriers on maintenance dialysis have been issued. No rigorously controlled treatment trials for treatment of hepatitis B with either interferon or lamivudine therapy ill dialysis patients are currently available.File | Dimensione | Formato | |
---|---|---|---|
Fabrizi_et_al-2008-Seminars_in_Dialysis.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
145.17 kB
Formato
Adobe PDF
|
145.17 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.